At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLRX Salarius Pharmaceuticals Inc
Trading 11-25 11:30:50 EST
1.50
+0.13
+9.49%
High1.50
Low1.37
Vol20.09K
Open1.37
D1 Closing1.37
Amplitude9.49%
Mkt Cap2.16M
Tradable Cap2.11M
Total Shares1.44M
T/O28.86K
T/O Rate1.43%
Tradable Shares1.40M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.